Positrigo AG

Positrigo AG is a Swiss medical imaging company specializing in dedicated brain Positron Emission Tomography (PET) systems. The company manufactures the NeuroLF, an ultra-compact, fully integrated brain PET scanner designed to make functional neuroimaging accessible and affordable for precision medicine applications. The NeuroLF system is particularly focused on early diagnosis of neurodegenerative diseases, including Alzheimer's disease and other dementia-related disorders. The company has achieved FDA clearance (July 2024) and CE Mark (October 2024) for its NeuroLF system, enabling commercialization in the US and Europe. Positrigo holds ISO 13485:2016 certification, demonstrating compliance with medical device quality management standards. The company manufactures and distributes its systems through a network of international distributors across Europe, the US, and other regions. Recent deployments include installations at The Neuron Clinic (first US outpatient neurology clinic), Beverly Hills Medical Imaging, University Hospital of Genoa (Italy), and LMU Hospital Munich (Germany). Positrigo operates a US subsidiary established in 2023 and launched the BrainPET Accelerator program in the US to support clinical adoption. The company is backed by significant venture funding and has received grants from Innosuisse and the European Innovation Council (EIC Fund).